These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 27405747

  • 1. Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib.
    Kasamatsu T, Saitoh T, Ino R, Gotoh N, Mitsui T, Shimizu H, Matsumoto M, Sawamura M, Yokohama A, Handa H, Tsukamoto N, Murakami H.
    Hematol Oncol; 2017 Dec; 35(4):711-718. PubMed ID: 27405747
    [Abstract] [Full Text] [Related]

  • 2. IL17A and IL23R gene polymorphisms affect the clinical features and prognosis of patients with multiple myeloma.
    Kasamatsu T, Kimoto M, Takahashi N, Minato Y, Gotoh N, Takizawa M, Matsumoto M, Sawamura M, Yokohama A, Handa H, Tsukamoto N, Saitoh T, Murakami H.
    Hematol Oncol; 2018 Feb; 36(1):196-201. PubMed ID: 28786198
    [Abstract] [Full Text] [Related]

  • 3. Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.
    Vangsted AJ, Klausen TW, Abildgaard N, Andersen NF, Gimsing P, Gregersen H, Nexø BA, Vogel U.
    Ann Hematol; 2011 Oct; 90(10):1173-81. PubMed ID: 21347685
    [Abstract] [Full Text] [Related]

  • 4. IL-10RB rs2834167 (A/G) polymorphism is associated with the susceptibility to systemic lupus erythematosus: evidence from a study in Chinese Han population.
    Peng H, Liu CY, Zhou M, Wen PF, Zhang M, Qiu LJ, Ni J, Liang Y, Pan HF, Ye DQ.
    Inflammation; 2013 Dec; 36(6):1218-24. PubMed ID: 23749100
    [Abstract] [Full Text] [Related]

  • 5. CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens.
    Qin XY, Lu J, Li GX, Wen L, Liu Y, Xu LP, Chang YJ, Liu KY, Jiang ZF, Huang XJ.
    Ann Hematol; 2018 Mar; 97(3):485-495. PubMed ID: 29264740
    [Abstract] [Full Text] [Related]

  • 6. Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone.
    Du J, Yuan Z, Zhang C, Fu W, Jiang H, Chen B, Hou J.
    Leuk Res; 2010 Nov; 34(11):1453-8. PubMed ID: 20122728
    [Abstract] [Full Text] [Related]

  • 7. No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma.
    Vangsted AJ, Søeby K, Klausen TW, Abildgaard N, Andersen NF, Gimsing P, Gregersen H, Vogel U, Werge T, Rasmussen HB.
    BMC Cancer; 2010 Aug 04; 10():404. PubMed ID: 20684753
    [Abstract] [Full Text] [Related]

  • 8. Polymorphisms of IL-10 affect the severity and prognosis of myelodysplastic syndrome.
    Kasamatsu T, Saitoh T, Minato Y, Shimizu H, Yokohama A, Tsukamoto N, Handa H, Sakura T, Murakami H.
    Eur J Haematol; 2016 Mar 04; 96(3):245-51. PubMed ID: 25941112
    [Abstract] [Full Text] [Related]

  • 9. Association of a PD-L2 Gene Polymorphism with Chronic Lymphatic Filariasis in a South Indian Cohort.
    Venugopal G, O'Regan NL, Babu S, Schumann RR, Srikantam A, Merle R, Hartmann S, Steinfelder S.
    Am J Trop Med Hyg; 2019 Feb 04; 100(2):344-350. PubMed ID: 30594267
    [Abstract] [Full Text] [Related]

  • 10. Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression.
    Jung SH, Choi HJ, Shin MG, Lee SS, Hwang EC, Jung TY, Cho MS, Yang DH, Ahn JS, Kim YK, Kim HJ, Lee JJ.
    Ann Hematol; 2016 Oct 04; 95(10):1645-51. PubMed ID: 27365142
    [Abstract] [Full Text] [Related]

  • 11. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
    Smetana J, Berankova K, Zaoralova R, Nemec P, Greslikova H, Kupska R, Mikulasova A, Frohlich J, Sevcikova S, Zahradova L, Krejci M, Sandecka V, Almasi M, Kaisarova P, Melicharova H, Adam Z, Penka M, Jarkovsky J, Jurczyszyn A, Hajek R, Kuglik P.
    Clin Lymphoma Myeloma Leuk; 2013 Apr 04; 13(2):123-30. PubMed ID: 23291040
    [Abstract] [Full Text] [Related]

  • 12. Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens.
    Du J, Huo J, Shi J, Yuan Z, Zhang C, Fu W, Jiang H, Yi Q, Hou J.
    Haematologica; 2011 May 04; 96(5):729-37. PubMed ID: 21228035
    [Abstract] [Full Text] [Related]

  • 13. The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD).
    Terragna C, Remondini D, Martello M, Zamagni E, Pantani L, Patriarca F, Pezzi A, Levi G, Offidani M, Proserpio I, De Sabbata G, Tacchetti P, Cangialosi C, Ciambelli F, Viganò CV, Dico FA, Santacroce B, Borsi E, Brioli A, Marzocchi G, Castellani G, Martinelli G, Palumbo A, Cavo M.
    Oncotarget; 2016 Mar 01; 7(9):9666-79. PubMed ID: 26575327
    [Abstract] [Full Text] [Related]

  • 14. Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment.
    Terpos E, Migkou M, Christoulas D, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Kanellias N, Iakovaki M, Panagiotidis I, Ziogas DC, Fotiou D, Kastritis E, Dimopoulos MA.
    Blood Cancer J; 2016 May 27; 6(5):e428. PubMed ID: 27232930
    [Abstract] [Full Text] [Related]

  • 15. PDCD1 and PDCD1LG1 polymorphisms affect the susceptibility to multiple myeloma.
    Kasamatsu T, Awata M, Ishihara R, Murakami Y, Gotoh N, Matsumoto M, Sawamura M, Yokohama A, Handa H, Tsukamoto N, Saitoh T, Murakami H.
    Clin Exp Med; 2020 Feb 27; 20(1):51-62. PubMed ID: 31620907
    [Abstract] [Full Text] [Related]

  • 16. TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma.
    Bagratuni T, Terpos E, Eleutherakis-Papaiakovou E, Kalapanida D, Gavriatopoulou M, Migkou M, Liacos CI, Tasidou A, Matsouka C, Mparmparousi D, Dimopoulos MA, Kastritis E.
    Br J Haematol; 2016 Jan 27; 172(1):44-7. PubMed ID: 26564000
    [Abstract] [Full Text] [Related]

  • 17. CRP/IL-6/IL-10 Single-Nucleotide Polymorphisms Correlate with the Susceptibility and Severity of Community-Acquired Pneumonia.
    Chou SC, Ko HW, Lin YC.
    Genet Test Mol Biomarkers; 2016 Dec 27; 20(12):732-740. PubMed ID: 27705004
    [Abstract] [Full Text] [Related]

  • 18. Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib.
    Minarik J, Scudla V, Ordeltova M, Bacovsky J, Pika T, Langova K.
    Eur J Haematol; 2009 Dec 01; 83(6):528-34. PubMed ID: 19624720
    [Abstract] [Full Text] [Related]

  • 19. Bortezomib and Thalidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up.
    Stork M, Sandecká V, Boichuk I, Adam Z, Krejci M, Brozova L, Sevcikova S, Pour L.
    Klin Onkol; 2019 Dec 01; 32(6):445-452. PubMed ID: 31842563
    [Abstract] [Full Text] [Related]

  • 20. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
    Sonneveld P, Goldschmidt H, Rosiñol L, Bladé J, Lahuerta JJ, Cavo M, Tacchetti P, Zamagni E, Attal M, Lokhorst HM, Desai A, Cakana A, Liu K, van de Velde H, Esseltine DL, Moreau P.
    J Clin Oncol; 2013 Sep 10; 31(26):3279-87. PubMed ID: 23897961
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.